Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 13.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoint |
| 14.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Cert |
Stammdaten
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Unternehmen & Branche
| Name | Bionano Genomics, Inc. |
|---|---|
| Ticker | BNGO |
| CIK | 0001411690 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Diagnostics & Research |
| SIC | 3826 · Laboratory Analytical Instruments |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 3,8 Mio. USD |
| Beta | 1,60 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 28,508,000 | -26,395,000 | -4.85 | 73,584,000 | 44,424,000 |
| 2025-09-30 | 10-Q | 7,367,000 | -8,503,000 | -1.59 | 79,062,000 | 49,799,000 |
| 2025-06-30 | 10-Q | 6,733,000 | -6,857,000 | -1.99 | 76,010,000 | 45,374,000 |
| 2025-03-31 | 10-Q | 6,457,000 | -3,102,000 | -1.15 | 78,414,000 | 48,188,000 |
| 2024-12-31 | 10-K | 30,776,000 | -112,017,000 | -88.13 | 76,670,000 | 35,375,000 |
| 2024-09-30 | 10-Q | 6,073,000 | -44,246,000 | -30.92 | 87,362,000 | 48,864,000 |
| 2024-06-30 | 10-Q | 7,771,000 | -16,224,000 | -14.41 | 129,364,000 | 80,335,000 |
| 2024-03-31 | 10-Q | 8,769,000 | -31,422,000 | -35.75 | 157,995,000 | 82,770,000 |
| 2023-12-31 | 10-K | 36,116,000 | -232,493,000 | -408.60 | 214,404,000 | 96,157,000 |
| 2023-09-30 | 10-Q | 9,318,000 | -112,566,000 | -3.22 | 181,904,000 | 118,999,000 |
| 2023-06-30 | 10-Q | 8,662,000 | -38,912,000 | -1.24 | 271,381,000 | 214,756,000 |
| 2023-03-31 | 10-Q | 7,415,000 | -37,124,000 | -1.23 | 292,151,000 | 231,486,000 |
| 2022-12-31 | 10-K | 27,802,000 | -132,596,000 | -4.58 | 307,502,000 | 249,400,000 |
| 2022-09-30 | 10-Q | 7,221,000 | -31,809,000 | -1.10 | 323,698,000 | 281,741,000 |
| 2022-06-30 | 10-Q | 6,670,000 | -32,158,000 | -1.13 | 321,552,000 | 284,734,000 |
| 2022-03-31 | 10-Q | 5,696,000 | -29,952,000 | -0.11 | 348,211,000 | 311,185,000 |
| 2021-12-31 | 10-K | 17,981,000 | -72,435,000 | -0.26 | 377,100,000 | 337,118,000 |
| 2021-09-30 | 10-Q | 4,655,000 | -20,753,000 | -0.07 | 359,657,000 | 341,565,000 |
| 2021-06-30 | 10-Q | 3,856,000 | -18,786,000 | -0.07 | 356,809,000 | 345,866,000 |
| 2021-03-31 | 10-Q | 3,168,000 | -9,947,000 | -0.04 | 384,861,000 | 362,718,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.